Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Renal Allograft Tolerance Through Mixed Chimerism
NCT01780454Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Mar 2013
- Primary completion
- Jun 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of siplizumab in end stage renal disease (ESRD), sponsored by Massachusetts General Hospital. Primary endpoint: Successful Withdrawal of Immunosuppressive Therapy at 5 years. Started Mar 2013; status: completed.
02
Drugs
siplizumab
03
Conditions
end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT01780454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01780454.